Abstract: A fast fluidized bed reactor, device and method for preparing para-xylene and co-producing light olefins from methanol and/or dimethyl ether and benzene, resolving or improving the competition problem between an MTO reaction and an alkylation reaction during the process of producing para-xylene and co-producing light olefins from methanol and/or dimethyl ether and benzene, and achieving a synergistic effect between the MTO reaction and the alkylation reaction. By controlling the mass transfer and reaction, competition between the MTO reaction and the alkylation reaction is coordinated and optimized to facilitate a synergistic effect of the two reactions, so that the conversion rate of benzene, the yield of para-xylene, and the selectivity of light olefins are increased.

Abstract: A process for the production of high purity toluene and para-xylene is described. More specifically, the process involves the production of high purity toluene produced via a light-desorbent selective adsorption process for para-xylene production, such as light desorbent para-xylene extraction, without the need for dedicated solvent extraction or olefin removal from the toluene stream.

Abstract: A gas conditioning system is described herein. The system includes a slug catcher configured to separate a hydrocarbon feed stream into a liquid stream and a gas stream, and a first hydrate inhibitor injection unit configured to lower a hydrate formation temperature of the gas stream using a first hydrate inhibitor. The system includes a pressure reduction unit, a first separation unit configured to remove a first liquid stream including the first hydrate inhibitor from the gas stream, a mercury removal unit, and an acid gas removal unit. The system also includes a second hydrate inhibitor injection unit configured to further lower the hydrate formation temperature of the gas stream using a second hydrate inhibitor, a cooling unit, a second separation unit configured to remove a second liquid stream including the second hydrate inhibitor from the gas stream, and a dehydration unit configured to produce a final treated gas stream.

Abstract: Methods for the production of para-xylene include flowing a xylenes-containing stream comprising PX, meta-xylene (MX), and ortho-xylene (OX), to a first crystallization stage. In addition, the methods include lowering a temperature of the xylenes-containing stream to below the eutectic point of the xylenes-containing stream within the first crystallization stage to crystallize at least some of the PX and at least some of one of both of the MX and the OX within the xylenes-containing stream. Further, the methods include separating the xylenes-containing stream into a first crystallization effluent stream and a first filtrate stream.

Abstract: A catalyst composition for converting an alcohol to olefins, the catalyst composition comprising the following components: (a) beta zeolite; (b) at least one element selected from the group consisting of zinc, magnesium, calcium, strontium, sodium, and potassium; and (c) at least one element selected from the group consisting of hafnium, yttrium, zirconium, tantalum, niobium, and tin; wherein the components (b) and (c) are independently within or on a surface of said beta zeolite. The catalyst may also further include component (d), which is copper or silver. Also described herein is a method for converting an alcohol to one or more olefinic compounds, the method comprising contacting the alcohol with a catalyst at a temperature of at least 100° C. and up to 500° C. to result in the alcohol being converted to the one or more olefinic compounds.

Abstract: An organic compound that emits red light having a long wavelength is represented by formula (1). In formula (1), R1 to R24 are each independently selected from the group consisting of a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryloxy group, a silyl group, and a cyano group.

Abstract: A process for the production of glycols is provided, the process comprising the steps of: (i) contacting a saccharide-containing feedstock with a catalyst system in a reactor in the presence of a reaction medium, a buffer system for controlling the pH within the reactor, and hydrogen; (ii) withdrawing a reactor product stream from the reactor; (iii) separating the reactor product stream into at least a glycol product stream and a hydrocarbon heavies stream; and (iv) recycling the hydrocarbon heavies stream at least partially back to the reactor; wherein components of the buffer system withdrawn from the reactor in the reactor product stream separate with the heavies stream and are recycled therewith.

Abstract: The invention relates to a process for methanol synthesis comprising the steps of providing a syngas feed stream comprising hydrogen and a mixture of carbon dioxide and carbon monoxide, wherein carbon dioxide represents from 1 to 50 mol % of the total molar content of the feed stream, carbon monoxide is contained from 0.1 to 85 mol % of the total molar content, and H2 is comprised from 5 to 95 mol % of the total molar content of the feed stream; providing an indium oxide catalyst selected from a bulk catalyst and a supported catalyst comprising indium oxide (In2O3) as the main active phase; putting in contact said stream with said catalyst at a reaction temperature of at least 373 K (99.85° C.) and under a pressure ranging of at least 1 MPa; and recovering the methanol effluents. The invention also relates to an indium oxide based catalyst.

Abstract: The invention relates to fused cyclooctyne compounds, and to a method for their preparation. The invention also relates to a conjugate wherein a fused cyclooctyne compound according to the invention is conjugated to a label, and to the use of these conjugates in bioorthogonal labeling, imaging and/or modification, such as for example surface modification, of a target molecule. The invention further relates to a method for the modification of a target molecule, wherein a conjugate according to the invention is reacted with a compound comprising a 1,3-dipole or a 1,3-(hetero)diene.

Abstract: A method for producing at least one oxidation product selected from the group consisting of acrolein and acrylic acid is provided. This method can alleviate concerns about deterioration of a gas-phase oxidation catalyst and reaction runaway in a restart period after a shutdown, and can allow the reaction to proceed in a stable state. Using a fixed-bed reactor filled with a gas-phase oxidation catalyst, at least one source gas selected from the group consisting of propylene and acrolein is subjected to a gas-phase contact oxidation reaction while a heating medium is caused to contact with or circulate through the fixed-bed reactor and thereby to heat the fixed-bed reactor. The temperature of the heating medium when the load is maximum in the restart period after the shutdown is controlled to be lower than the temperature of the heating medium when the load is maximum in an initial start-up period.

Abstract: A method for recovering a composition enriched in 3-hydroxypropionic acid by providing the fermentation broth, acidifying the fermentation broth; reducing the total sulfate ion and phosphate ion concentration of the resulting gaqueous solution to produce a reduced ion aqueous solution; distilling the resulting reduced ion aqueous solution and recovering the resulting aqueous distillation product comprising 3-hydroxypropioriic acid

Abstract: New host-protective molecules containing conjugated triene and diene double bonds with each carrying a 13-carbon position alcohol and were derived from n-3 docosapentaenoic acid (DPA, C22:5) were produced in neutrophil-endothelial co-cultures, and they are present in human and mouse tissues after sterile inflammation or infection. These compounds, termed 13-series resolvins (RvT), demonstrated potent protective actions increasing mice survival during Escherichia coli infections. Their biosynthesis during neutrophil-endothelial cell interactions was initiated by endothelial cyclooxygenase-2 (COX-2) and increased by atorvastatin via S-nitrosylation of COX-2. Atorvastatin and RvT were additive in E. coli infections in mice where they accelerated resolution of inflammation and increased survival >60%. Results documented novel host protective molecules in bacterial infections, namely RvT, derived from n-3 DPA via transcellular biosynthesis and increased by atorvastatin.

Abstract: The present invention provides a production method of a multifunctional acrylate with a reduced tin content which includes adding an acid to a mixture containing an organotin compound and a multifunctional acrylate and distilling the mixture containing the acid.

Abstract: This invention relates to the field of producing bioplastics. Specifically, it relates to a method of producing all key ingredients of bioplastic making from pumpkins and making of bioplastic with these ingredients. More specifically, glycerin and other chemicals are extracted from pumpkin seed oil and mixed with starches that in the pumpkin flesh to make bioplastic. The bioplastic produced with the method as disclosed in this invention possess superior properties in tensile strength and biodegradability compared to bioplastic.

Abstract: A method of preparing an ester by reacting a carboxylic acid with a (C1-C36)alcohol in the presence of a catalyst that is suitable for preparing carboxylic acid esters of monomeric carboxylic acids in high yield. The method reduces by-products of the reaction, in particular esters of dimeric, trimeric and/or oligomeric carboxylic acids. The method requires a minimal excess of alcohol and does not require removal of water and/or carboxylic acid ester from the reaction mixture. The method is particularly suitable for the reaction of hydroxyalkylcarboxylic acids and fatty alcohols.

Abstract: The present disclosure provides a process for the preparation of compounds of formula (III), compounds of formula (V), and corresponding salts of formula (IV). The compounds made by the methods and processes of the invention are particularly useful for administration in humans and animals.

Abstract: A salicyl fumarate derivative, and its general structural formula (A) is: Wherein the structural formula (A), R1 is one of H+, Na+, K+ or NH4+. R2 is one of fumaric acid ester products. It has the general structural formula of the combination of salicylic acid and fumaric acid through esterification reaction. This category of compounds possesses good effects in treatment of neurodegenerative diseases.

Abstract: The invention provides novel analogues of enacyloxin Ha and their pharmaceutically acceptable salts, metabolites, isomers (e.g. stereoisomers) and prodrugs. Such compounds are effective in the treatment of infections caused by Gram-negative bacteria such as Acinetobacter baumannii. Compounds in accordance with the invention include those of formula (A), and their pharmaceutically acceptable salts, metabolites, isomers (e.g. stereoisomers) and prodrugs: In formula (A): X is 0 or NRx (where R* is either H or C1-3 alkyl, e.g. CH3); R1 is a 5- or 6-membered, saturated or unsaturated, carbocyclic ring optionally substituted by one or more substituents, or R1 is an optionally substituted straight-chained or branched C1-6 alkyl group (e.g. C1-3 alkyl group); R2 is H, F, Cl, Br, I or CH3; R3 is H or OH; R8 is a straight-chained or branched C1-8 alkyl group (e.g.

Abstract: A method for producing an alkyl nitrite by bringing an aqueous solution containing nitric acid and an alkanol into contact with a gas including nitrogen monoxide and thereby producing an alkyl nitrite, in which the reaction temperature is 60° C. to 100° C., is provided.

Abstract: The present invention, discloses optically pure compounds of l-Norepinephrine and its acid addition salts and hydrates and process for the preparation thereof. Specifically, the present invention discloses optically pure compounds of l-Norepinephrine bitartrate, its process of preparation and pharmaceutical compositions comprising the same.

Abstract: This invention relates to performance chemicals field, it discloses a novel and green process for simultaneous productions of formamides as well as mono- and multi-functional acrylamides under very mild conditions and with high efficiency. These substances are widely useful as industrial solvents or raw materials, in particular acrylamides are important olefinically-unsaturated polymerizable monomers in photo-curing materials.

Abstract: The invention is based on the discovery of a new bacterial compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Studying the mechanisms implicated in analgesic properties of the probiotic Escherichia coli strain Nissle 1917 (EcN), inventors characterized, the amino fatty acids produced by EcN, which display the Ecn analgesic properties. One of these compounds inhibits the hypersensitivity to colorectal distension induced by capsaicin, which is a very powerful nociceptive compound and acts via the GABA B receptor. Furthermore, inventors demonstrate that this compound is able to cross the cellular epithelial barrier (such as the intestinal epithelium). Thus, the invention relates to a lipopetide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.

Abstract: The present disclosure provides crystalline polymorphic and amorphous forms of (R)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N?-(2-ethyl-3-methoxy-benzoyl)-hydrazide (Compound 1) or (S)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N?-(2-ethyl-3-methoxy-benzoyl)-hydrazide (Compound 2). The present disclosure further provides compositions comprising crystalline polymorphic and amorphous forms of Compound 1 or Compound 2 and an excipient, methods of making crystalline polymorphic or amorphous forms of Compound 1 or Compound 2, and methods of using crystalline polymorphic or amorphous forms of Compound 1 or Compound 2 to regulate gene expression in a cell or in a subject.

Abstract: A guanidine of the formula (I) and to the use thereof as catalyst for the crosslinking of a functional compound, especially a polymer having silane groups. The guanidine of the formula (I) described is preparable in a simple method via a polyfunctional carbodiimide adduct from the readily available raw materials, and is largely odorless at room temperature and of low toxicity. In spite of its comparatively high molecular weight, it accelerates the crosslinking of functional compounds surprisingly well, and such compositions do not have a tendency to migration-related defects such as separation, exudation or substrate soiling.

Abstract: An ether-bridged dication is provided with two monovalent cations bonded via a carbon chain having ether group(s). The ether-bridged dication, monovalent cations, and anions are contained together within an ionic liquid electrolyte which is applied to a charge storage device. The ether-bridged dication, the ionic liquid electrolyte, and the charge storage device have operational abilities at room temperatures or below, and a reachable working potential of 3.5 V.

Abstract: An onium salt and a composition having high sensitivity and excellent pattern characteristics such as LWR, which is preferably used for a resist composition for a lithography process using two active energy rays of a first active energy ray such as an electron beam or an extreme ultraviolet and a second active energy ray such as UV.

Abstract: An organic tellurium compound is disclosed having a versatility that, when used as a living radical polymerization initiator, it is applicable to polymerization of a vinyl monomer in an aqueous vehicle without using any surfactant or dispersant. The organic tellurium compound is represented by a general formula (1), where R1 and R2 each independently represent a hydrogen atom or an alkyl group having 1 to 8 carbon atoms, A represents an alkali metal atom or an alkaline earth metal atom, x=1 when A is monovalent, x=½ when A is divalent, and R3 is represented by a general formula (2), where in the general formula (2) R4 represents a hydrogen atom or an alkyl group having 1 to 8 carbon atoms, R5 and R6 each independently represent an alkylene group having 2 to 8 carbon atoms, and a represents an integer from 0 to 10.

Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I), or a pharmaceutically acceptable salt thereof, and its therapeutic use.

Abstract: The invention relates to compounds of formula wherein R, R1, R2, X, and Y are as defined herein and to a pharmaceutically suitable acid addition salt thereof. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

Abstract: The present disclosure provides pyrrolidine carboxamide compounds having Formula I and the pharmaceutically acceptable salts and solvates thereof, wherein A, B, X, Y, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.

Abstract: A crystalline form of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide is disclosed. The crystalline form has a diffraction peak when a diffraction angle, 2?, is 16.66±0.2°, 17.54±0.2°, 21±0.2°, 22.16±0.2°, or 30.96±0.2°. The crystalline form can be dissolved quickly in water with a solubility greater than or equal to 90 mg/mL, features high bioavailability, has high stability at high temperature, is suitable for preparing multiple pharmaceutical compositions, and can prepare multiple formulations, such as tablets, capsules, dripping pills, sustained-release and controlled-release formulations, and lyophilized powder for injection. The method for preparing the crystalline form is carried out under a mild condition, is easy to operate, introduces a few impurities, and features good reproducibility, an easy-to-control production process and high safety, and is suitable for industrial production.

Abstract: The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Abstract: The present disclosure generally provides compounds useful for treating cancer. In some aspects, the disclosure provides small-molecule histone deacetylase inhibitors (HDIs) that are chemically modified to have one or more moieties that include hydrophobic portions. In some aspects, the disclosure provides compositions that include such modified HDIs and a protein, such as albumin or albumin mimetics. Further, the disclosure provides various uses of these compounds and compositions.

Abstract: An organic compound having a naphtho fluoranthene core and a hetero aromatic group bonded to a specific position of the naphtho fluoranthene core, an organic light-emitting diode and an organic light-emitting device including the compound are disclosed. Since the organic compound has a narrow Stokes Shift between an absorption wavelength and an emission wavelength, the organic compound has a broad overlapped area between its absorption peak and an emission peak of a delayed fluorescent material, and therefore it can emit blue light with high color purity. It is possible to manufacture an organic light-emitting diode (OLED) and an organic light-emitting device that enhance luminous efficiency and color purity using the organic compound.

Abstract: Compounds with activity as modulators of cell adhesion are disclosed. The compounds are derivatives of piperidin-4-amine. In some embodiments, a compound can be linked to a targeting agent, a pharmaceutically active substance and/or a support material. Methods for enhancing or inhibiting classical cadherin-mediated functions are also disclosed. The compounds can be used for the treatment or prevention of a variety of diseases including cancer. Compositions and devices, including skin patches comprising a compound are also disclosed. In addition, methods of synthesis of the compounds are provided.

Abstract: The present disclosure provides methods for enantioselective synthesis of cyclic and acyclic ?-quaternary carboxylic acid derivatives via nickel-catalyzed allylic alkylation.

Abstract: A method for separating and purifying 2-chloro-3-trifluoromethylpyridine useful as an intermediate for medicines, agrochemicals, and the like is provided. The method includes: 1) in the process of producing chloro ?-trifluoromethylpyridine compounds by allowing a ?-methylpyridine compound to react with chlorine and hydrogen fluoride in a reaction apparatus, allowing a ?-trifluoromethylpyridine compound to react with chlorine in a reaction apparatus, or allowing a chloro ?-trichloromethylpyridine compound to react with hydrogen fluoride in a reaction apparatus, 2) fractionating a liquid mixture containing chloro ?-trifluoromethylpyridine compounds from the reaction apparatus, and 3) separating and purifying 2-chloro-3-trifluoromethylpyridine from the liquid mixture.

Abstract: The present invention relates to a method for purifying a compound represented by the formula (I), the method including treating a mixture containing the compound represented by the formula (I) and a compound represented by the formula (II) with an aqueous solution of a basic compound. where, in the formula (I), R1 represents a hydrogen atom or a chlorine atom; in the formula (II), R2, R3 and R4 are the same or different from each other and represent a hydrogen, a chlorine atom or a fluorine atom independently, at least one of R3 and R4 represent a chlorine atom or a fluorine atom, and, in the case where R3 represents a chlorine atom, R4 represents a chlorine atom or a fluorine atom.

Abstract: Despite its power in identifying highly potent ligands for select protein targets, conventional medicinal chemistry is limited by its low throughput and lack of proteomic selectivity information. We seek to develop a chemoproteomic approach for discovering covalent ligands for protein targets in an unbiased, high-throughput manner. Tripartite probe compounds composed of a heterocyclic core, an electrophilic ‘warhead’ and an alkyne tag have been designed and synthesized for covalently labeling and identifying targets in cells. We have developed a novel condensation reaction to prepare 2-chloromethylquinoline (2-CMQ), a novel electrophilic heterocycle. These chloromethylquinolines potently and covalently bind to a number of cellular protein targets including Prostaglandin E Synthase 2 (PTGES2), a critical regulator of cell proliferation, apoptosis, angiogenesis, inflammation, and immune surveillance.

Abstract: Pyrazolc derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the serotonin 5HT2A receptor. Formula (Ia). Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia. NOS schizophrenia and related disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.

Abstract: A method for preparing 5-(4-bromophenyl)-4,6-dichloropyrimidine is provided. The method comprises the steps of: preparing methyl p-bromophenylacetate (Intermediate I) by catalytic esterification of p-bromophenylacetic acid, and then reacting with dimethyl carbonate to synthesize 2-(4-bromophenyl)-malonic acid-1,3-dimethyl ester (Intermediate 2), cyclizing with formamidine hydrochloride to obtain 5-(4-bromophenyl)-4,6-dihydroxypyrimidine (Intermediate 3), and then chlorinating to give the product 5-(4-bromophenyl)-4,6-dichloropyrimidine. In the process of preparing Intermediate 1 in the present invention, a solid acid is used as a catalyst. Moreover, in the process of preparing Intermediate 2, sodium methoxide is used as a base in place of sodium hydride or sodium amide used in the prior art. Furthermore, Intermediate 3 is prepared by a one-pot process.

Abstract: The present invention describes arylamine derivatives which are substituted by diazanaphthalene groups, in particular for use in electronic devices. The invention furthermore relates to a process for the preparation of the compounds according to the invention and to electronic devices containing same.

Abstract: The invention provides a method for treating a disease or disorder in a mammal which is caused by induced NFkB transcriptional activity in cells of the mammal, the method comprising administering to the mammal a compound that specifically inhibits one or more of CDK8 and CDK19.

Abstract: The present disclosure discloses sodium ion channel inhibitors, pharmaceutically acceptable salts and polymorphs thereof, and uses thereof. Specifically, the present disclosure discloses a polymorph of a compound of formula (X) and a preparation method thereof. The preparation method of the present disclosure is simple in operation and suitable for industrialization. The polymorph prepared by the preparation method has advantages of good stability, low hygroscopicity and high water solubility.

Abstract: The present invention relates to a process for preparing amorphous form of Sacubitril/Valsartan sodium salt of Formula-II and pharmaceutical composition comprising thereof.

Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.

Abstract: The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.

Abstract: A polymerizable compound has a practical low melting point, excellent solubility in a general-purpose solvent, and can produce an optical film at low cost, exhibits low reflected luminance, and achieves uniform conversion of polarized light over a wide wavelength band, an optically anisotropic article.

Abstract: Various aspects of this disclosure relate to methods to lower the activation energy of the cannabinoid decarboxylation reaction by performing the decarboxylation reaction in the gas phase.

Abstract: Various aspects of this patent document relate to the rapid purification and decarboxylation of cannabinoids by vaporization and condensation.